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1. Introduction
Echinococcosis is considered the most common parasitic disease and the most 
widespread zoonotic infection caused by several cestode species belonging to the 
genus Echinococcus [1].
This parasite has 12 different genus types, though four major species are 
known to cause human parasitic disease: Echinococcus granulosus (E. granulosus), 
Echinococcus multilocularis, Echinococcus vogeli, and Echinococcus oligarthrus [2].
E. granulosus is the causative organism of cystic echinococcosis, a small-sized 
tapeworm measuring approximately 2–7 mm in length with at least 10 different 
genome patterns and distinct genetic markers [1].
2. Parasitology
The parasitic life cycle involves two mammalian hosts. The intermediate hosts 
include members of the ungulates such as sheep, goats, and pigs. The definitive host 
of this parasite is the dog and other members of canids.
The adult parasite inhabits the small intestine of a definitive host and eggs, 
containing infective oncospheres, are produced. Subsequently, free eggs as well as 
cestode segments are excreted through the stool of the host into the environment [1].
Following an oral uptake of eggs by an intermediate host, a larval stage 
(metacestode) develops in several internal organs, mainly the liver and lungs, 
after a larval migration through the blood and lymph vessels. Typically, numer-
ous protoscoleces are produced by the mature metacestode, each with the poten-
tial to develop into an adult cestode after oral ingestion by a suitable definitive 
host [3].
Humans are accidental or aberrant hosts that are not essential to the natural 
Echinococcus life-cycle. The eggs, after being ingested, develop as a cyst (hydatid 
cyst) inside the accidental host organs. Larval infection leading to the hydatid 
disease is characterized by metacestode long-term growth in the intermediate host. 
The parasitic cystic structure is typically filled with a clear hydatid fluid [4]. The 
inner germinating membrane of the cyst provides germination and the outer cystic 
layer features a laminated part. A granulomatous inflammatory reaction leads to a 
fibrous tissue constitution walling the cyst [5].
Developing cysts are responsible for the morbidity and the mortality related to 
the disease [3].
Cystic echinococcosis (CE) occurs worldwide. E. granulosus is known to occur 
on all continents but high parasite prevalences are found in endemic areas such as 
central Asia, the Mediterranean Basin, the Russian Federation, Africa (northern 
and eastern regions), Australia, and South America [1, 3].
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Although Echinococcosis is regarded as an eradicable disease, it leads to serious 
economic losses for public health systems and agricultural sectors in endemic areas 
[6]. Therefore, numerous control programs reveal that preventive measures for 
the interruption of parasitic life cycle may relatively reduce the prevalence and the 
incidence of the hydatid disease [3, 7].
3. Diagnosis
3.1 Clinic
CE clinical presentation reflects the presence of one or more unilocular fluid-
filled cysts. Liver and lungs are most commonly affected: about 70% of cysts involve 
the liver and the lungs are involved in 20% followed by other organs such as spleen, 
kidney, brain, breasts, and bone.
The disease course is typically slow and most patients have an asymptomatic 
disease course for several years. Otherwise, the cystic slow growth rate is esti-
mated at 1–5 mm per year and patients develop symptoms as the cyst gradually 
grows [5, 8–10].
In the early stage of echinococcosis, clinical manifestations are mild. At later 
stages, damaged tissues and organs can become dysfunctional with the occurrence 
of symptoms related to cystic complications.
Symptoms are nonspecific and the diagnosis is often incidental, based on immu-
nological tests and imaging such as standard radiology, ultrasonography (US), 
computed axial tomography (CT), and magnetic resonance imaging (MRI).
3.2 Serology
Serologic diagnostic methods play an important complementary role. They are 
used in order to support the radiological diagnosis and for follow-up of patients 
after surgical or pharmacological management.
There are multiple immunological responses to the disease. Mild immune 
response is noted with rugged and intact cysts, whereas complicated cysts (leaking 
or ruptured cysts) tend to show a strong immune response [4].
Serodiagnosis consists of the detection of specific serum antibodies by multiple 
immunodiagnostic tests. An optimum test should be specific with high sensitivity. 
There are considerable differences between the various serological tests, concerning 
the specificity as well as the test sensitivity.
In routine laboratory applications, the indirect hemagglutination (IHA) is 
often nonspecific, while the enzyme-linked immunosorbent assay (ELISA) using 
crude hydatid cyst fluid has a high sensitivity (up to 95%) with low specificity. 
Concomitant use of both tests (IHA and ELISA) is associated with diagnostic 
sensitivity over than 85–96% [1, 11].
False-positive serological findings are revealed in 20% of patients with 
CE, which is mainly related to cross-reactions with other parasitic diseases. 
Furthermore, seronegativity rate is relatively higher in cases with nonactive disease 
stages, in patients treated for autoimmune or malignant pathologies and during 
pregnancy [12]. Cysts in the bone, brain and calcified cysts often show no or low 
immunological response [5].
Immunoblot analysis is generally used when IHA and ELISA findings are not 
definitive. The immunological diagnosis is established by the detection of specific 
serum antibodies. Immunological methods often use the most specific antigens:  
E. granulosus, antigen B, and antigen 5 (Ag5) [1, 13].
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3.3 Imaging
US is considered as the first choice imaging modality in the diagnosis and 
follow-up. It is a convenient and efficient imaging tool that demonstrates the cystic 
number, location, and size. Furthermore, US can guide the interventional radiol-
ogy, which is often available, safe, and cost-efficient method with no radiation. 
Therefore, it can be used in endemic areas with large populations to make a prompt 
diagnosis. It mainly explores abdominal location.
Typically, the liver involvement is shown as a mixed echogenic, heterogeneous 
pattern with irregular contours with multiple distributed calcific foci, whereas, the 
radiologist must be aware of differential diagnosis in less typical appearance. The 
criteria for ultrasonographic cystic classification of liver was first made by Gharbi 
in 1981, and then, improved by the World Health Organization (WHO) in 2001 [5]. 
Cysts in other sites like the brain and the lung are not well demonstrated with US 
and it require the use of other screening techniques. Conventional radiography can 
be required as the initial imaging modality to diagnose thoracic and bone involve-
ment. The X-ray findings are nonspecific and are visualized as multiple small 
opacities [14].
CT and MRI are mainly used in some cases, where US does not provide definitive 
findings. These imaging tools are necessary for illustrating the lesions morphologic 
features in intra-abdominal organs, which are involved through a direct invasion 
from the primary lesion or disseminated disease.
They are also indicated in patients with sub-diaphragmatic location, extra-
abdominal sites (in bone and soft tissues involvement), complicated cysts such 
as cysto-biliary fistulae and abscess, cases with extra-abdominal dissemination. 
Moreover, CT and MRI can be useful for the preoperative evaluation and for 
patient’s follow-up examination.
The radiologist should be familiar with multimodality imaging findings of this 
particular disease. Thus, according to the organ involvement, the lesion can be con-
fused with other differential diagnosis including neoplasms, metastatic neoplasms, 
or abscess [14].
4. Treatment
There are several treatment approaches for echinococcosis, including moni-
toring (watch and wait strategy), chemotherapy, interventional radiology, and 
surgery. Indications for one or more management options are complex and depend 
on the cyst features, medical and surgical equipment availability and the patient’s 
cooperation. Therefore, it is preferable to refer patients to reference treatment 
centers for echinococcosis in order to get the suitable management [15].
4.1 Medical treatment
The choice of the therapeutic modality is related to cyst stage, size, site, and 
comorbidities.
Medical treatment using parasitostatic drugs such as benzimidazoles (mebenda-
zole and albendazole) is mainly recommended for inoperable patients and patients 
with disseminated disease. Drug therapy should be administered continuously for 
at least 3 months. However, prolonged treatment has a high cost with multiple tera-
togenic side effects [16]. Moreover, chemotherapy can be used as a complementary 
therapy to surgery or to prevent metastasis and secondary cystic sites. However, it is 
not recommended in the treatment of inactive or calcified cysts [17].
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The watch and wait strategy is a therapeutic option for uncomplicated cysts with 
multiple involvements. It requires a regular long-term monitoring of liver function 
tests and leukocyte counts [17].
4.2 Percutaneous treatment
The percutaneous treatment modality is defined as an option for the manage-
ment of cysts in the liver and other abdominal locations. This procedure is divided 
into two techniques: (1) PAIR technique is the best known, consisting of the 
destruction of the germinal membrane following the use of a scolicidal agent and 
(2) modified catheterization techniques aiming at the entire endocyst evacuation. 
This approach is a mini invasive procedure comparing to the surgery, but cysts 
containing daughter vesicles are not the best indication for percutaneous treat-
ment because of the high risk of spread into the peritoneal cavity and into the 
biliary tract [5].
4.3 Surgical treatment
Surgery should be carefully evaluated. The decision-making is based on the 
characteristics of the hydatid cyst as the cyst type, number, size, location, and the 
presence or not of associated complications. It is well recommended for large cysts 
containing multiple daughter vesicles, symptomatic and complicated cysts, cysts 
with superficial location that may be ruptured spontaneously or following a benign 
trauma, infected cysts and cysts with close contact with vessels or adjacent vital 
organs. Furthermore, it can be an option for patients not suitable for percutaneous 
treatment.
The surgical approach is aiming to parasite inactivation, evacuation of the endo-
cyst with the prevention of contamination, germinal layer removal, and residual 
cavity management [18].
Regarding the abdominal sites (typically the hepatic involvement), there are 
two surgical approaches consisting of a conservative surgery and radical procedure 
using open or laparoscopic surgery [19].
Conservative procedures consist of the parasitic cyst contents removal such as 
daughter vesicles and germinative membrane, whereas the pericyst is retained. The 
residual cavity is carefully explored to research any evidence of cystic biliary tract 
communication and then managed according to different techniques: capitonnage, 
omentoplasty, or external drainage.
Surgeons should cover the operating field with a scolicidal agent in order to 
avoid the parasites spillage and the peritoneal cavity contamination.
Conservative surgery is simple, safe with relatively reduced operative time, but 
has high morbidity and recurrence rates [19].
Radical surgery is the first therapeutic choice suitable for total excision of the 
entire parasitic lesion. Whenever possible, complete resection is required because 
radical surgical procedures are superior to conservative surgical methods and may 
cure definitively the patient [18].
The radical surgery target is the removal of the whole cyst with the parasitic 
contents and pericystic tissue.
Radical procedures includes: partial cystectomy, total cystic removal through an 
open or closed pericystectomy, and hepatic resection.
During the pericystectomy, a proper cleavage plane between the inner layer and 
the outer cystic layer may limit the liver parenchyma damage.
Hepatic resection is more difficult, takes longer operative time with higher risk 
of blood loss but lower cystic recurrence rates.
5Introductory Chapter: Overview on Echinococcosis
DOI: http://dx.doi.org/10.5772/intechopen.88972
Comparing to conservative treatment, radical surgery is preferable due to lower 
morbidity, mortality, and reoccurrence rates [19].
Laparoscopic management of hydatid cysts with abdominal (hepatic or extra-
hepatic sites) has its place among management approaches. It is a mini invasive 
surgery that can be safely achieved in particular cases after patients’ selection.
Laparoscopy has several advantages including: better visualization of the perito-
neal cavity and internal organs, prompt postoperative discharge, limited postopera-
tive morbidity, and good esthetic outcomes [18].
There is lower frequency of hydatid disease in extra-hepatic sites. The manage-
ment and the proper therapeutic approach depend essentially on cystic site and the 
organ involved. Generally, when the removal of the cysts is complete, the prognosis 
is good with low rate of recurrence [20].
5. Follow-up
A long-term follow-up for patients managed for hydatid disease should be 
planned because recurrences may occur in some cases. The patient monitoring 
is mainly based on imaging techniques (US, CT, and MRI) at short intervals. 
Serological tools and specific serum antibodies dosage support imaging techniques 
and can reflect metastode viability. Moreover, the monitoring of parasitostatic 
plasma level is necessary to adjust the therapeutic range and to prevent long-term 
treatment side effects [20].
Currently, planning for the echinococcosis control relies on the interruption of 
parasitic life cycle. The disease can be prevented by hygiene improvement in the 
slaughtering of livestock, public education campaigns, periodic deworming of dogs, 
and adequate destruction of infected offal. Vaccination of dogs with recombinant 
proteins provides encouraging prospects for prevention and control [21].
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